Allergan PLC's stock is trading at its lowest point since December 2013 and investors increasingly are showing their displeasure with the company's current management, including two hedge funds that have gone public with a demand to split the CEO and chairman roles held by Brent Saunders.
Activist Investors Seek Action At Allergan, But Are They Aligned?
Investors want to separate the CEO and chairman roles held by Brent Saunders, among other demands, but it's unclear whether new investor Carl Icahn – a prior Saunders supporter – will pursue the same causes.
More from Strategy
• By
Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.
• By
PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.